Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.29USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
59,760
52-wk High
$4.04
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Sophiris Bio Q4 Loss Per Share $0.13
Wednesday, 21 Mar 2018 04:05pm EDT 

March 21 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.13.Q4 EARNINGS PER SHARE VIEW $-0.11 -- THOMSON REUTERS I/B/E/S.SOPHIRIS - EXPECTS CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS.  Full Article

Sophiris Bio posts Q3 loss per share $0.09
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports third quarter financial results and key corporate highlights.Q3 loss per share $0.09.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Sophiris Bio Inc - qtrly ‍total operating expenses $3.3 million versus $3.7 million.  Full Article

SOPHIRIS BIO ENTERED INTO LOAN AND SECURITY AGREEMENT OF UP TO $10 MLN IN TWO TERM LOANS​
Wednesday, 13 Sep 2017 04:05pm EDT 

Sept 13 (Reuters) - Sophiris Bio Inc :SOPHIRIS BIO- ‍ANNOUNCED THAT IT ENTERED INTO A LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK AND MAY BORROW UP TO $10 MILLION IN TWO TERM LOANS​.  Full Article

Sophiris Bio Q1 loss per share $0.09
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports first quarter financial results and key corporate highlights.Q1 loss per share $0.09.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Sophiris Bio - expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018.  Full Article

Sophiris Bio Q4 loss per share $0.02
Monday, 27 Mar 2017 09:00am EDT 

Sophiris Bio Inc : Sophiris Bio reports fourth quarter and full year 2016 financial results and key corporate highlights . Q4 loss per share $0.02 . Sophiris Bio Inc - at dec 31, 2016, co had cash, cash equivalents and securities available-for-sale of $29.0 million and working capital of $27.8 million . Sophiris Bio Inc - expects to receive six-month biopsy data for all patients in late 2017 or early 2018 . Sophiris Bio Inc - expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018 .Sophiris Bio- not planning on pursuing second phase 3 trial in bph,unless can secure development partner to fund new trial,obtain other financing.  Full Article

SNB still sees correction risk in Swiss real estate market

ZURICH, Sept 20 The Swiss National Bank (SNB) again warned that Swiss mortgage and real estate markets could tumble, pointing to continued increases in banks' mortgage lending and a rise in housing prices amidst growing vacancies as persistent imbalances.